Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ024
- Development stage
- Preclinical
- Lead developer
- Tuojie Biotech
- Modality
- Small Molecules
01
Overview
TJ024 (also known as TJ-024) is an investigational small molecule therapeutic being developed by Tuojie Biotech (Shanghai Tuojie Biological Technology) for the treatment of non-alcoholic steatohepatitis (NASH), a condition recently renamed to metabolic dysfunction-associated steatohepatitis (MASH). The drug is currently in the early stages of development and is featured in Tuojie's research pipeline alongside other small molecule and small nucleic acid candidates. While the specific molecular target of TJ024 has not been publicly disclosed in detail, it represents part of the company's strategic focus on metabolic diseases and chronic liver conditions.
Beyond the preview
Go deeper on TJ024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ024.